http://www.autolus.com
Autolus Therapeutics plc Company Intro
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Industry
Healthcare
Autolus Therapeutics plc Headquaters
Forest House
London,W12 7RZ
United Kingdom
Autolus Therapeutics plc Share price
17 May 2023 12:49 GMT
$2.4700
-0.05 (-1.98 %)
Autolus Therapeutics plc Market cap
$427.495 M
WMC RANKING
2024
Autolus Therapeutics plc # 273
BiotechnologyLatest Autolus Therapeutics plc News
12 Feb 2024
Analyst Expresses Confidence in Autolus Therapeutics with Increased Price Target
On February 12, 2024, Gil Blum, an esteemed analyst at Needham, expressed his confidence in Autolus Therapeutics (NASDAQ:AUTL) by maintaining a Buy rating.
12 Feb 2024
Autolus Therapeutics (NASDAQ:AUTL) PT Raised to $9.00
Needham & Company LLC increased their price target on shares of Autolus Therapeutics from $8.00 to $9.00 and gave the stock a "buy" rating in a research...
12 Feb 2024
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up on Analyst Upgrade
Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report)'s stock price gapped up before the market opened on Monday after Needham & Company LLC raised their...
WMC Market Score
WMC Market to Revenue Score
Autolus Therapeutics plc Market Financials
Revenue, Expenses, Profit
| Company | Currency | Revenue | Expense | Profit | Market Cap | WMC Sector Score |
| Autolus Therapeutics plc | USD | $1,646 | $170,428 | $-145,487 | $4,275M | 273 |
| Regeneron Pharmaceuticals, Inc. | USD | $9,197,600 | $3,997,800 | $4,003,800 | $804,390B | 1 |
| Vertex Pharmaceuticals Incorporated | USD | $6,414,881 | $2,617,257 | $2,762,032 | $878,880B | 2 |
| Alexion Pharmaceuticals, Inc. | USD | $6,261,601 | $2,747,200 | $681,800 | $ 0.00 | 3 |
| ALK-Abello A/S | USD | $3,556,000 | $1,893,000 | $66,000 | $189,400B | 4 |
Market Analytics
Company Search vs Top 4 Industry Competitors
Total Autolus Therapeutics plc Social Followers vs Top 4 Industry Competitors
Autolus Therapeutics plc Post vs Top 4 Industry Competitors
Autolus Therapeutics plc Digital Footprint By Size vs Top 4 Industry Competitors
Autolus Therapeutics plc Digital Footprint By Change Rate vs Top 4 Industry Competitors
Autolus Therapeutics plc WMC Market Score Calculations
| Details | Revenue | Total Social Followers | Total Social Posts | Search Volume | Digital Footprint Size | Digital change (New Pages) | WMC Market Score |
| Autolus Therapeutics plc | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 |
| Regeneron Pharmaceuticals, Inc. | 100 | 25.50 | 16.15 | 70 | 0 | 0 | 39.85 |
| Vertex Pharmaceuticals Incorporated | 69.75 | 35.68 | 8.95 | 100 | 0 | 0 | 51.56 |
| Alexion Pharmaceuticals, Inc. | 68.08 | 100 | 100 | 80 | 0 | 0 | 100 |
| ALK-Abello A/S | 38.66 | 0 | 0 | 0 | 0 | 0 | 0 |
Book a demo
Book a free one-on-one demo with one of our team and see exactly how the WMC business intelligence platform can help you protect and grow revenue.
* required fields
You'll learn how to:
- 1. Automatically monitor your entire digital landscape including competitors
- 2. View all new industry activity in real time
- 3. Monitor your position in your industry
- 4. Enrich your reports and strategy
- 5. Empower your teams with knowledge
